Background: This study investigated whether rosiglitazone might affect dementia risk.

Methods: The Taiwan’s National Health Insurance database was used to enroll a cohort of 1:1 matched-pairs of ever and never users of rosiglitazone based on propensity score from patients with new onset type 2 diabetes during 1999-2006. The patients were alive on January 1, 2007 and were followed-up for dementia until December 31, 2011.

Results: A total of 5048 pairs of never users and ever users were identified. The incident case numbers were 127 and 121, respectively. The overall hazard ratio was 0.895 (95% confidence interval: 0.696-1.151) for ever versus never users. The hazard ratios for the first (<12.1 months), second (12.1-25.1 months) and third (>25.1 months) tertiles of cumulative duration were 0.756 (0.509-1.123), 0.964 (0.685-1.357) and 0.949 (0.671-1.341), respectively. When cumulative duration was treated as a continuous variable, the hazard ratio was 1.000 (0.992-1.008). Subgroup analyses conducted in ever users and never users of metformin and in patients whose diabetes was diagnosed during three different periods of time, i.e., 1999-2000, 2001-2003 and 2004-2006, all supported a neutral effect of rosiglitazone.

Conclusions: Rosiglitazone has a neutral effect on dementia risk in patients with type 2 diabetes mellitus.

Disclosure

C. Tseng: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.